Employer file: ICON

ICON plc is the second-largest contract research organization on earth, behind IQVIA and ahead of everyone else. It is headquartered in Dublin, reported about 41,900 employees across 55 countries as of 2024, and posted roughly $8.28 billion in revenue that year. If you work in clinical research long enough, you will either work here or interview here.

How it got this big

ICON did not grow to this size organically. In 2021 it bought PRA Health Sciences, a Raleigh-based CRO, in a cash-and-stock deal worth about $12 billion. That acquisition roughly doubled the company and is why so much of ICON's US clinical staff sits in North Carolina, the same corridor where IQVIA is headquartered. Two of the three biggest CROs run their US operations out of the same metro area, which matters when you are negotiating: your next employer and your current one may recruit from the identical talent pool.

What the public record shows

ICON is publicly traded (ICLR), so its financials are real numbers rather than recruiter estimates. Read them the way this site reads everything: as context, not as your offer. Revenue tells you the company's scale and its exposure to pharma R&D budgets. It does not tell you what a CRA II clears in your city.

For that, the honest anchors are government filings and job ads. Our salaries page carries per-person H-1B disclosures for the CRO sector: senior CRAs filed in the low $120,000s, CRA IIs in the high $90,000s to $105,000, senior statistical programmers around a $122,400 median. ICON's own bands will sit near those, adjusted for location and how hard they want the specific hire. When an ICON recruiter quotes a range, check it against the filed numbers rather than against the aggregator averages, which lump every level together and read low.

The pressure to know about

ICON entered 2026 under visible strain. Analysts have flagged slow big-pharma R&D spending and clinical trial demand that has not fully recovered, and the stock has taken it on the chin. That backdrop is not gossip; it is the weather you would be joining. It shapes how much leverage you have, how aggressively the company backfills departures, and how exposed a given program is to being trimmed.

None of that makes ICON a bad employer. Scale brings real things: therapeutic breadth, sponsor relationships, internal mobility, and a name that travels on a resume. But a company managing margin pressure negotiates differently than one racing to staff a boom. Go in knowing which one you are talking to.

Questions worth asking

Before you sign with ICON, or any CRO this size, ask the questions the org chart hides. Is this role sponsor-dedicated (FSP) or does it float across the ICON portfolio? Dedicated roles trade variety for stability and sometimes for a different pay band. How many active studies would you carry, and what is the site load per study? What is the travel expectation in writing, and how are cancelled-visit days paid? What happened to the last person in this seat?

What we cannot tell you from the outside

We cannot tell you ICON's internal salary bands, its current merit budget, or which programs are safe. No public source can. That gap is the entire reason this community exists. If you work at ICON now, or left recently, your anonymous datapoint on the salary survey is worth more to the next candidate than any of the public figures above. It is the one number nobody can file for you.